This was a discovery study that established the concept of taking advantage of the immune system to detect cancer.

There is really intriguing evidence that this particular gene fusion is the causative agent of prostate cancer.

It was a serendipitous discovery, something very surprising to us.

These 22 markers ended up being the best combination of markers that allow us to most effectively diagnose prostate cancer.

It's a controversial arena -- the PSA is a marker of prostate bulk and size, but it's highly expressed in benign prostate disease as well as cancer -- so in that context it's not a specific marker.

Initially, we envision this new test could be used as a supplement to PSA.